A definitive agreement has been reached in which New Jersey-based Actavis (NYSE:AGN) will acquire Ireland-based pharma company Warner Chilcott (NASDAQ:WCRX) in an all-stock transaction valued at $8.5 billion, the companies announced today.
The proposed deal will expand on the existing specialty pharma business of Actavis, particularly therapeutics in areas including women's health, gastroenterology, urology, and dermatology.
At closing, which is expected by year's end, Warner Chilcott shareholders will receive 0.16 shares of the newly combined company, tentatively called "New Actavis," for each share of Warner Chilcott they own. Based on Actavis' closing price of $125.50 a share on May 17, that amounts to $20.08 for each Warner Chilcott share, a 43% premium over Warner's 30-day volume-weighted average trading price, ending on May 9. Actavis shareholders will receive one share of New Actavis for each share owned at closing.
New Actavis intends to incorporate in Ireland after closing, and will be led by the Actavis executive management team. Activis CEO and President Paul Bisaro was quoted as saying, "The combination of Actavis and Warner Chilcott creates a strong specialty brand portfolio focused in therapeutic categories with strong growth potential, and is supported by a deep pipeline of development programs."
Existing shareholders of both Actavis and Warner Chilcott must approve the transaction. The boards of directors of each company have unanimously agreed to terms of the deal.
Fool contributor Tim Brugger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Allergan Stock Downgraded: What You Need to Know
Allergan's valuation depends heavily on its growth -- but that growth could be at risk.
Allergan Keeps Heading Lower. Is It Time to Buy?
Allergan's stock slips for the third straight month in October.
How Allergan plc Lost $4 Billion in Q3 and Still Performed Quite Well
Hint: Successful acquisitions and Botox trump write-offs.